NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study

Phase 3

Active, not recruiting

Conditions: Clear Cell Renal Cell Carcinoma
Metastatic Malignant Neoplasm in the Bone
Metastatic Malignant Neoplasm in the Soft Tissue
Stage IV Renal Cell Cancer AJCC v8
Metastatic Malignant Neoplasm in the Lymph Nodes
Metastatic Malignant Neoplasm in the Viscera
Rhabdoid Tumor of the Kidney
Sarcomatoid Renal Cell Carcinoma
Stage III Renal Cell Cancer AJCC v8

Interventions: Procedure: Biospecimen Collection
Procedure: Bone Scan
Drug: Cabozantinib
Procedure: Computed Tomography
Biological: Ipilimumab
Procedure: Magnetic Resonance Imaging
Biological: Nivolumab
Other: Quality-of-Life Assessment
Other: Questionnaire Administration

First Posted Date: 2019-01-04

Last Posted Date: 2025-04-09

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 1175

Registration Number: NCT03793166

Locations: 🇺🇸
Illinois CancerCare-Peru, Peru, Illinois, United States
🇺🇸
Valley Radiation Oncology, Peru, Illinois, United States
🇺🇸
Greater Regional Medical Center, Creston, Iowa, United States

and more 858 locations

Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer

Phase 3

Active, not recruiting

Conditions: Lung Non-Squamous Non-Small Cell Carcinoma
Stage IIIC Lung Cancer AJCC v8
Stage IIIB Lung Cancer AJCC v8
Stage IV Lung Cancer AJCC v8

Interventions: Procedure: Biospecimen Collection
Drug: Carboplatin
Procedure: Computed Tomography
Procedure: Magnetic Resonance Imaging
Biological: Pembrolizumab
Drug: Pemetrexed
Procedure: Positron Emission Tomography

First Posted Date: 2019-01-04

Last Posted Date: 2025-05-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 600

Registration Number: NCT03793179

Locations: 🇺🇸
University of South Alabama Mitchell Cancer Institute, Mobile, Alabama, United States
🇺🇸
Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States
🇺🇸
Anchorage Radiation Therapy Center, Anchorage, Alaska, United States

and more 1094 locations

Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma

Phase 2

Active, not recruiting

Conditions: Follicular Lymphoma
Non-Hodgkin's Lymphoma
NHL

Interventions: Biological: Rituximab
Drug: Copanlisib

First Posted Date: 2018-12-28

Last Posted Date: 2025-05-28

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 33

Registration Number: NCT03789240

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma

Phase 2

Active, not recruiting

Conditions: Ganglioneuroblastoma
High Risk Neuroblastoma

Interventions: Procedure: Autologous Hematopoietic Stem Cell Transplantation
Drug: Carboplatin
Drug: Cisplatin
Drug: Cyclophosphamide
Drug: Dexrazoxane
Biological: Dinutuximab
Drug: Doxorubicin
Drug: Etoposide
Radiation: External Beam Radiation Therapy
Drug: Isotretinoin
Drug: Melphalan
Biological: Sargramostim
Drug: Thiotepa
Drug: Topotecan
Drug: Vincristine

First Posted Date: 2018-12-26

Last Posted Date: 2025-03-21

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 42

Registration Number: NCT03786783

Locations: 🇺🇸
Saint Jude Children's Research Hospital, Memphis, Tennessee, United States
🇳🇿
Starship Children's Hospital, Grafton, Auckland, New Zealand
🇦🇺
The Children's Hospital at Westmead, Westmead, New South Wales, Australia

and more 7 locations

Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers

Phase 2

Completed

Conditions: Hepatocellular Carcinoma
Metastatic Colorectal Cancer
Liver Metastasis
Hepatocellular Cancer
Metastatic Pancreatic Cancer

Interventions: Drug: nivolumab
Drug: tadalafil
Drug: oral vancomycin

First Posted Date: 2018-12-24

Last Posted Date: 2023-07-11

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 22

Registration Number: NCT03785210

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer

Phase 3

Active, not recruiting

Conditions: Muscle Invasive Bladder Carcinoma
Bladder Urothelial Carcinoma
Stage II Bladder Cancer AJCC v8
Stage IIIA Bladder Cancer AJCC v8

Interventions: Procedure: Biopsy of Bladder
Drug: Atezolizumab
Drug: Cisplatin
Procedure: Computed Tomography
Procedure: Cystoscopy
Drug: Gemcitabine
Drug: Fluorouracil
Procedure: Magnetic Resonance Imaging
Drug: Mitomycin
Other: Quality-of-Life Assessment
Radiation: Radiation Therapy
Other: Survey Administration
Procedure: Transurethral Resection of Bladder Tumor

First Posted Date: 2018-12-13

Last Posted Date: 2025-04-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 475

Registration Number: NCT03775265

Locations: 🇺🇸
Aurora Cancer Care-Grafton, Grafton, Wisconsin, United States
🇺🇸
Bellin Memorial Hospital, Green Bay, Wisconsin, United States
🇺🇸
The Hospital of Central Connecticut, New Britain, Connecticut, United States

and more 364 locations

Pevonedistat and Belinostat in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Phase 1

Terminated

Conditions: Refractory Acute Myeloid Leukemia
Recurrent Myelodysplastic Syndrome
Recurrent Acute Myeloid Leukemia
Refractory Myelodysplastic Syndrome

Interventions: Drug: Belinostat
Drug: Pevonedistat

First Posted Date: 2018-12-12

Last Posted Date: 2025-06-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 18

Registration Number: NCT03772925

Locations: 🇺🇸
Moffitt Cancer Center-International Plaza, Tampa, Florida, United States
🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States

and more 3 locations

Ixazomib and Pevonedistat in Treating Patients With Multiple Myeloma That Has Come Back or Does Not Respond to Treatment

Phase 1

Completed

Conditions: Recurrent Multiple Myeloma
Refractory Multiple Myeloma

Interventions: Drug: Ixazomib Citrate
Drug: Pevonedistat

First Posted Date: 2018-12-10

Last Posted Date: 2023-09-26

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 8

Registration Number: NCT03770260

Locations: 🇺🇸
University of Kentucky/Markey Cancer Center, Lexington, Kentucky, United States
🇺🇸
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

and more 6 locations

Tissue Acquisition and Genomics Analysis of Breast Cancer and Other Gynecologic Malignancies

Conditions: Ovarian Cancer
Breast Cancer
Uterine Cancer

First Posted Date: 2018-12-04

Last Posted Date: 2025-06-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 500

Registration Number: NCT03762733

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocyte Leukemia

Phase 1

Terminated

Conditions: Leukemia
B-Cell
Lymphocytic
Chronic

Interventions: Drug: rhIL-15
Biological: Obinutuzumab

First Posted Date: 2018-11-29

Last Posted Date: 2022-03-22

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 1

Registration Number: NCT03759184

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy